EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

NivobotulinumtoxinA in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines in Two Phase 3 Clinical Trials

William Coleman, Vince Bertucci iD, Shannon Humphrey, Joely Kaufman-Janette, Terrence Keaney, David Pariser, Nowell Solish iD, David Wirta, Robert A Weiss

Aesthetic Surgery Journal · 2025

DOI: 10.1093/asj/sjae233 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Aesthetic Surgery Journal, 2025. Verfasst von William Coleman und 8 weiteren Autor:innen. Hauptthemen laut MEDLINE: Skin Aging, Botulinum Toxins, Type A, Neuromuscular Agents, Cosmetic Techniques. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medytox, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Botulinum neurotoxins in aesthetic medicine require reconstitution before administration, which may be inconvenient and present errors among injectors.

Objectives

The aim of this study was to evaluate the efficacy and safety of ready-to-use nivobotulinumtoxinA liquid formulation for the treatment of glabellar lines (GL) with or without treatment of lateral canthal lines (LCL).

Methods

Two multicenter, phase 3, double-blind, randomized trials enrolled participants with moderate-to-severe GL (Study 001) or moderate-to-severe GL + LCL (Study 005). Participants received double-blind nivobotulinumtoxinA (20 U) or placebo (Period 1) then ≤2 open-label nivobotulinumtoxinA GL treatments (Period 2) in Study 001 or double-blind nivobotulinumtoxinA 20 U (GL), nivobotulinumtoxinA 44 U (GL + LCL), or placebo (Period 1) then ≤2 double-blind injections of the same treatment (Period 2) in Study 005. The composite primary endpoint was the proportion of participants achieving a ≥2-grade improvement on a facial wrinkle scale at maximum frown on investigator and participant assessment; coprimary endpoints were investigator- and participant-assessed FWS “none or mild” ratings.

Results

At Day 30, significantly higher responder rates were observed for the composite primary endpoint with GL treatment alone (Study 001, 46.1%; Study 005, 45.1%) and GL + LCL (Study 005, 41.3%) vs placebo (0%; all P < .001). Responder rates of “none or mild” by investigator and participant assessment, respectively, were significantly higher for GL treatment alone (Study 001, 77.2% and 65.0%; Study 005, 74.3% and 68.8%) and GL + LCL (Study 005, 74.0% and 61.2%) vs placebo (all P < .001). Adverse events were similar between treatment groups and placebo.

Conclusions

Liquid nivobotulinumtoxinA was effective and well tolerated for treating moderate-to-severe GL alone or with LCL. Level of Evidence: 1 (Therapeutic)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin AgingBotulinum Toxins, Type ANeuromuscular AgentsCosmetic TechniquesHumansDouble-Blind MethodFemaleMiddle AgedMaleAdultTreatment OutcomeAgedForehead

Substanzen

Botulinum Toxins, Type ANeuromuscular Agents

Autor:innen und Institutionen

ORCID-Profile: Vince Bertucci, Nowell Solish

Förderung

  • Medytox, Inc

Zitieren

APA

Coleman, W., Bertucci, V., Humphrey, S., Kaufman-Janette, J., Keaney, T., Pariser, D., Solish, N., Wirta, D., & Weiss, R. A. (2025). NivobotulinumtoxinA in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines in Two Phase 3 Clinical Trials. Aesthetic Surgery Journal. https://doi.org/10.1093/asj/sjae233

Vancouver

Coleman W, Bertucci V, Humphrey S, Kaufman-Janette J, Keaney T, Pariser D, et al. NivobotulinumtoxinA in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines in Two Phase 3 Clinical Trials. Aesthetic Surgery Journal. 2025. doi:10.1093/asj/sjae233

BibTeX
@article{Coleman2025,
  author = {Coleman, William and Bertucci, Vince and Humphrey, Shannon and Kaufman-Janette, Joely and Keaney, Terrence and Pariser, David and Solish, Nowell and Wirta, David and Weiss, Robert A},
  title = {NivobotulinumtoxinA in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines in Two Phase 3 Clinical Trials},
  journal = {Aesthetic Surgery Journal},
  year = {2025},
  doi = {10.1093/asj/sjae233}
}
Kostenlos starten →